METHADONE FOR THE TREATMENT OF CHRONIC PAIN CANCER

DROGERIA MARFAN S.A.C.,0 个研究点目标入组 0 人开始时间: 1999年9月27日最近更新: 2023年9月4日

试验速览

暂无简介。

•1. Patient diagnosed with cancer confirmed by histology
•2. Age between 18 and 70 years.
•3. Presence of a pain lasting more than 30 days.
•4. Pain secondary to cancer or its treatment.
•5. Somatic, visceral, neuropathic or mixed pain
•6. Intensity of pain of moderate, intense or very intense degree
•7. Kamofsky equal to or greater than 60.
•8. Patients who have used the 1st and 2nd therapeutic steps of the WHO require the use of a strong opioid.
•9. Patients who accept and can sign an informed consent.
•10. Patients who can read, write and do not have cognitive impairment.
•11. Patients able to keep a diary during their participation in the study.

•1. Presence of a pain maintained by the sympathetic. The presence of a pain maintained by the sympathetic is suspected when there is a severe pain, burning-like, associated with allodynia (pain secondary to innocuous stimulation in normal skin), hyperpathy (presence of pain after a stimulus is finished), changes trophic skin and its annexes, hard edema and osteoporosis.
•2. Vital functions (blood pressure, heart rate and respiratory rate unstable or abnormal.
•3. Pregnant or lactating patient.
•4. Presence of liver, kidney or respiratory failure, asthma, chronic obstructive pulmonary disease, intracranial hypertension or a history of paralytic ileus.
•5. Allergy to morphine or other opioids.
•6. Patients scheduled for surgery, chemotherapy, radiotherapy or hormonotherapy during the study period.
•7. Patients who received chemotherapy or radiotherapy, or change in the hormonal regimen in the 14 days prior to the study.

发起方

DROGERIA MARFAN S.A.C.,